Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Finished Goods (2016 - 2018)

Anika Therapeutics has reported Finished Goods over the past 8 years, most recently at $4.6 million for Q3 2018.

  • Quarterly Finished Goods fell 20.31% to $4.6 million in Q3 2018 from the year-ago period, while the trailing twelve-month figure was $4.6 million through Sep 2018, down 20.31% year-over-year, with the annual reading at $4.7 million for FY2017, 3.02% up from the prior year.
  • Finished Goods was $4.6 million for Q3 2018 at Anika Therapeutics, down from $5.2 million in the prior quarter.
  • Over five years, Finished Goods peaked at $6.8 million in Q1 2018 and troughed at $3.1 million in Q1 2015.
  • The 5-year median for Finished Goods is $4.6 million (2018), against an average of $4.6 million.
  • Year-over-year, Finished Goods skyrocketed 147.88% in 2014 and then tumbled 41.93% in 2015.
  • A 5-year view of Finished Goods shows it stood at $3.2 million in 2014, then grew by 9.3% to $3.5 million in 2015, then increased by 29.64% to $4.5 million in 2016, then grew by 3.02% to $4.7 million in 2017, then fell by 0.81% to $4.6 million in 2018.
  • Per Business Quant, the three most recent readings for ANIK's Finished Goods are $4.6 million (Q3 2018), $5.2 million (Q2 2018), and $6.8 million (Q1 2018).